The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS

NCT03151005 on ClinicalTrials.gov · last registry update 2023-12-04

Finished 1 April 2021, after enrolling 70 people. Primary outcome, as filed: Assessment of Reproductive Functions. liraglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Xinqiao Hospital of Chongqing
Sponsor type: Other
Enrollment: 70
Started: 2017-07-01
Primary completion: 2021-04-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Assessment of Reproductive Functions

Conditions studied

Polycystic Ovary Syndrome (PCOS) · Overweight · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.